New combo drug for obesity enters early human testing
NCT ID NCT06916065
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage study tested the safety and tolerability of a new drug called eloralintide, given alone or with another drug (tirzepatide), in 188 adults with overweight or obesity. Participants received weekly injections under the skin, and researchers monitored side effects and how the drugs moved through the body. The goal was to gather initial safety data, not to prove weight loss effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
Conditions
Explore the condition pages connected to this study.